At a glance
ClinicalIndex Comparison RecordPhase 2Active· 46 enrolled
Drug / intervention
enzalutamidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers
In Brief
A Phase 2 clinical trial evaluating enzalutamide for Salivary Cancer. Active but no longer recruiting, targeting 46 participants across 287 sites.
Detailed Summary
This study will test any good and bad effects of the study drug called enzalutamide. Enzalutamide could shrink the cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by at least 30% compared to its present size, in at least 1 out of 5 patients. Enzalutamide is not FDA approved to treat salivary gland cancer, but it has already been FDA-approved to treat other cancers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSalivary Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Astellas Pharma US, Inc.
Timeline
Phase 2Active
2016201720182019202020212022202320242025202620272028
First PostedApr 2016
Enrollment StartSep 2016
Primary CompletionFeb 2019
TodayJul 2026
Study CompletionJul 2028
First PostedApr 25, 2016
Enrollment StartSep 14, 2016
Primary CompletionFeb 21, 2019
Study CompletionJul 5, 2028
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 10.2 years ago
Interventions
enzalutamidedrug
oral